Financhill
Back

Arbutus Biopharma Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Buy
51

ABUS
Arbutus Biopharma

Last Price:
3.87
Seasonality Move:
20.32%

7 Day Trial

ALL ACCESS PASS

$ 7

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!

Arbutus Biopharma Price Quote

$3.87
+0.01 (+-2.27%)
(Updated: November 5, 2024 at 5:11 AM ET)

Arbutus Biopharma Key Stats

Buy
51
Arbutus Biopharma (ABUS) is a Buy

Day range:
$3.86 - $3.96
52-week range:
$1.70 - $4.73
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
67.12
P/B ratio:
5.95%

Volume:
848.8K
Avg. volume:
808.8K
1-year change:
101.04%
Market cap:
$728.7M
Revenue:
$18.1M
EPS:
$-0.45

How Much Does Arbutus Biopharma Make?

Is Arbutus Biopharma Growing As A Company?

  • What Is Arbutus Biopharma's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.63%
  • What Is Arbutus Biopharma's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Arbutus Biopharma Stock Price Performance

What Is Arbutus Biopharma 52-Week High & Low?

Arbutus Biopharma Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Arbutus Biopharma?

  • How Much Debt Does Arbutus Biopharma Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Arbutus Biopharma Have?
    Cash and short term investments quarterly total is $142M
  • What Is Arbutus Biopharma’s Book Value Per Share?
    Book value per share is 0.65

Is Arbutus Biopharma Cash Flow Positive?

  • What Is ABUS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$72.9M
  • What Is Arbutus Biopharma’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $54.3M
  • What Is Arbutus Biopharma’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $54.2M

Arbutus Biopharma Return On Invested Capital

  • Is Management Doing A Good Job?
    ABUS return on invested capital is -64.55%
  • What Is Arbutus Biopharma Return On Assets?
    ROA measures how assets are converting to revenues and is -48.78%
  • What Is ABUS Return On Equity?
    ROE is a measure of profitability and is -64.55%

Arbutus Biopharma Earnings Date & Stock Price

Arbutus Biopharma Competitors

  • Who Are Arbutus Biopharma's Competitors?
    Below is a list of companies who compete with Arbutus Biopharma or are related in some way:
    • Biomarin Pharmaceutical Inc (BMRN)
    • Cidara Therapeutics Inc (CDTX)
    • Cue Biopharma Inc (CUE)
    • FibroGen Inc (FGEN)
    • GlycoMimetics Inc (GLYC)

Arbutus Biopharma Dividend Yield

Arbutus Biopharma Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -15.74%
Revenue: -62.89% -2.07%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 5.01
Upside from Last Price: 29.68%

Major Shareholders

  • How many ABUS shares are owned by institutional investors?
    161.8M ABUS shares are owned by institutional investors
  • How many ABUS shares are owned by insiders?
    6.8M ABUS shares are owned by insiders